Aytu Biopharma, Inc.
AYTU
$2.13
-$0.05-2.29%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 9.19% | -8.24% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.19% | -8.24% | |||
| Cost of Revenue | 17.84% | -3.67% | |||
| Gross Profit | 4.77% | -10.42% | |||
| SG&A Expenses | 8.02% | 20.87% | |||
| Depreciation & Amortization | 18.47% | -51.79% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 11.32% | 6.19% | |||
| Operating Income | -30.98% | -335.00% | |||
| Income Before Tax | -638.63% | 110.11% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -638.63% | 109.88% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -638.63% | 109.92% | |||
| EBIT | -30.98% | -335.00% | |||
| EBITDA | -54.78% | -136.25% | |||
| EPS Basic | -606.78% | 107.13% | |||
| Normalized Basic EPS | -606.61% | 112.64% | |||
| EPS Diluted | -1,264.29% | 97.35% | |||
| Normalized Diluted EPS | -1,144.53% | 106.13% | |||
| Average Basic Shares Outstanding | 6.31% | 39.01% | |||
| Average Diluted Shares Outstanding | -48.47% | 186.78% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||